BioSpace News Archive

Agilent Technologies Inc. (NYSE: A) today announced the release of the Agilent Seahorse XF Pro Analyzer, featuring new pharma-oriented workflow solutions incorporating advanced experimental design and analysis tools.

RELIEF THERAPEUTICS Holding SA announced that its wholly owned subsidiary, APR Applied Pharma Research SA, has received a Notice of Allowance from the U.S. Patent and Trademark Office for Patent Application No. 16/713,052 entitled, “Ready to Use Diclofenac Packs.”.

GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, reported that Leber Hereditary Optical Neuropathy subjects treated with LUMEVOQ® continued to experience significantly improved vision four years after a single injection of the gene therapy.

Innovent Biologics, Inc. announced that the Hong Kong Department of Health (DH) has approved Pemazyre®.

XPhyto Therapeutics Corp. is pleased to provide an update on the integration of 3a-diagnostics GmbH into XPhyto’s German operations.

ERYTECH Pharma announced presentation of results of two trials evaluating eryaspasein advanced pancreatic cancerat the American Society of Clinical Oncology Gastrointestinal Cancers Symposium on January 21, 2022.

Harbour BioMed announced that, it has successfully completed the dosing of first patient in phase Ib/IIa trial at the stage of dose expansion of its anti-CTLA-4 antibody in combination therapy with toripalimab for patients suffering from advanced melanoma and other solid tumors.